الفهرس Only 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Hepatitis C virus (HCV) is a major public health problem and is considered the most common etiology of chronic liver disease in Egypt. HCV decompensated patients have a median of survival of 2 years with limited options of treatment even with currently used direct antiviral treatment. Silymarin is the most commonly used herbal product by individuals with chronic liver disease for its anti - inflammatory, anti - viral, anti-oxidant and antifibrotic effects in the liver. Aimed to assess the effects of silymarin in high dose on the clinical and biochemical status of chronic HCV associated decompensated liver cirrhosis. The study was conducted on 62 chronic HCV decompensated cirrhotic patients. Patients were randomised according to silymarin treatment plans into: group A: included 31 received silymarin in dose of 1050mg / day. group B: included 31 received silymarin in dose of 420mg / day. All patients were subjected to baseline history taking, laboratory evaluation, abdominal U / S, Child sore calculation, quality of life questionnaire (Qol). Follow up was done every 2 weeks for 12 weeks